CellReady

Cell Ready

Biotechnology, 2100 Old Highway 8 Nw, New Brighton, Minnesota, 55112, United States, 51-200 Employees

wilsonwolf.com

  • LinkedIn

phone no Phone Number: +16*********

Who is CELLREADY

CellReady is specifically designed to cut two years, and millions of dollars, off the path that cell and gene therapy (CGT) companies take to acquire the meaningful clinical inflection po...

Read More

map
  • 2100 Old Highway 8 Nw, New Brighton, Minnesota, 55112, United States Headquarters: 2100 Old Highway 8 Nw, New Brighton, Minnesota, 55112, United States
  • 2023 Date Founded: 2023
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Billion and Over
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8062 | NAICS Code: 541110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from CELLREADY

CellReady Org Chart and Mapping

Employees

Minette Ty

Manager, Clinical Quality Assurance

Dan Welch

Director of Product Development

John Wilson

Cellready Founder, CEO, VP of Quality

Ashton Rowe

Quality Assurance Specialist

Aaron Lindorfer

Product Development Intern

Ash Yang

Medical Device Assembler

Kathleen Haggard

Human Resources / Finance

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding CellReady

Answer: CellReady's headquarters are located at 2100 Old Highway 8 Nw, New Brighton, Minnesota, 55112, United States

Answer: CellReady's phone number is +16*********

Answer: CellReady's official website is https://wilsonwolf.com

Answer: CellReady's revenue is $1 Billion and Over

Answer: CellReady's SIC: 8062

Answer: CellReady's NAICS: 541110

Answer: CellReady has 51-200 employees

Answer: CellReady is in Biotechnology

Answer: CellReady contact info: Phone number: +16********* Website: https://wilsonwolf.com

Answer: CellReady is specifically designed to cut two years, and millions of dollars, off the path that cell and gene therapy (CGT) companies take to acquire the meaningful clinical inflection points that investors demand. CGT companies are funded by investors that expect to see their money generate meaningful clinical data before they make additional investments. But that rarely happens. Instead of spending the money on clinical data, CGT companies burn through 5%-10% of their investor's money each month while they struggle to create the essential building blocks of their CGT company, such as a quality management system, scalable manufacturing process, and a CMC section that is sure to clear FDA scrutiny. The CGT industry now faces a crisis. Investors no longer tolerate this time-consuming approach that leaves them empty handed. CellReady solves the problem by allowing CGT companies to hit the ground running with all of the essential building blocks they need to quickly gather meaningful clinical data. And CellReady is not driven solely by profit. CellReady will provide CGT companies with an optimized, scalable, and standardized G-Rex centric cell manufacturing process at virtually no charge, a nimble quality management system for free, ready-made sections of the CMC that will clear FDA review, and a vast array of expertise in all technical and business aspects of running a successful CGT company.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access